Format

Send to

Choose Destination
World J Gastrointest Pathophysiol. 2014 Nov 15;5(4):450-6. doi: 10.4291/wjgp.v5.i4.450.

Biomarkers of Barrett's esophagus.

Author information

1
Yasser Mahrous Fouad, Reem Yehia, Gastroenterology and Hepatology Unit, Tropical Medicine Department, Minia University, Minia 11432, Egypt.

Abstract

Barrett's esophagus is the strongest risk for esophageal adenocarcinoma (EAC). Metaplasia in patients with BE may progress to dysplasia and then invasive carcinoma. Well-defined diagnostic, progressive, predictive, and prognostic biomarkers are needed to identify the presence of the disease, estimate the risk of malignant transformation, and predict the therapeutic outcome and survival of EAC patients. There are many predictive and prognostic markers that lack substantial validation, and do not allow stratification of patients with gastroesophageal reflux disease in clinical practice for outcome and effectiveness of therapy. In this short review we summarize the current knowledge regarding possible biomarkers, focusing on the pathophysiologic mechanisms to improve prognostic and therapeutic approaches.

KEYWORDS:

Barrett’s esophagus; Biomarkers; Esophageal adenocarcinoma

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center